Teva sees 25% of EpiPen market by year end

  • Teva Pharmaceutical (NYSE:TEVA) expects its generic version of Mylan's (NASDAQ:MYL) EpiPen to have about 25% share of the U.S. market by the end of 2019.
  • The company is already selling its product for adults and plans to start supply of a junior version for young kids in 3-4 months, CEO Kare Schultz declared.
  • Mylan also has a generic version of its EpiPen, which is priced at around $300, similar to Teva's product.
  • TEVA +1.1% premarket

Recommended For You

Comments (7)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.